Retinal pigmented epithelial (RPE) cell integrity is critical to the maintenance of retina functions and RPE cells do not proliferate in adults. The activation of RPE results in cell proliferation which may be associated with proliferative retinopathy and choroidal melanoma. Mitogen-activated protein kinase (MAPK) is believed to be a key participant in the response to mitogenic stimuli. We therefore investigated the involvement of the extracellular signal-regulated protein kinase (ERK) 1 and 2 during the induction of RPE cell proliferation. After foetal calf serum (FCS) stimulation activation of the Ras/Raf/ERK signalling pathway was detected by Western blotting and immunochemistry, with specific anti-phosphosignalling protein antibodies. Pharmacological and antisense (AS) oligonucleotide (ODN) strategies were used to analyse the signalling involved in FCS-induced RPE cell proliferation. Activation of the small G protein Ras and, to a lesser extent of Raf-1, the kinase directly downstream from Ras, was necessary to FCS-induced cell proliferation. MEK1/2 and ERK1/2 were activated during cell proliferation. Inhibition of MEK1/2 with UO 126 completely abolished ERK1/2 activation and reduced cell proliferation by 33 -43%. ERK1/2 depletion by an AS ODN approach reduced cell proliferation by 27 -33%, confirming the role of ERK1/ 2 in the FCS stimulation of RPE cells. We also investigated the role of PKA/cAMP, one of the major inhibitory pathways of ERK1/2. PKA blockade did not modify ERK1/2 activation or cell proliferation. In contrast, agents that increased cAMP concentration, abolished RPE proliferation, and MEK/ERK activation. Moreover, inhibition of the cAMP-activated small G protein Rap1, partially reversed the inhibitory effects of cAMP on cell proliferation and MEK/ERK activation. The requirement for Ras and ERK1/2, the lack of ERK1/2 regulation by PKA and the cAMP/Rap1 counter-regulatory pathway for ERK-mediated cell proliferation suggest complex regulation of signalling in RPE cells. These data may have important implications for the development of more selective models for retinal anti-proliferative therapies.
Introduction
Cell proliferation is regulated by a complex array of signalling pathways and by the integration of these pathways, generating a net signalling input that converges on a defined target such as the phosphorylation of transcription factors and proteins regulating the cell cycle. The Ras GTP-binding pathway plays a central role in transmitting cell proliferation signals. Once activated, it facilitates activation of the serine/ threonine kinase Raf (Daum et al., 1994) . This pathway mediates apparently conflicting cellular responses, such as proliferation, growth arrest, differentiation and senescence, depending on the duration and strength of the stimuli and cell type (Zimmermann and Moelling, 1999) . In this pathway, activated Raf phosphorylates and activates the downstream kinases MAP kinase kinase/ERK kinase (MEK1/2), which in turn phosphorylate and activate the MAP kinases ERK1/2 (Dhanasekavan and Premkumar Reddy, 1998) . Upon activation, ERK1/2 are translocated to the nucleus, where they phosphorylate and activate transcription factors. Enhanced transcriptional activity leads to the induction of immediate early genes and mitogenic activity (Davis, 1995) . In striking contrast, increasing intracellular cAMP concentration strongly inhibits cell growth and division (Sevetson et al., 1993) . The presumed mediator of the inhibitory effect on cell proliferation is the cAMP-dependent protein kinase (PKA) which has been reported to inhibit the Ras/ ERK1/2 signalling pathway (Cook and McCormick, 1993; McKenzie and Pouyssegur, 1996) . However, the exact point at which the ERK1/2 signalling pathway is inhibited by PKA is still a matter of some controversy and remains to be clearly identified. In striking contrast, it has been reported that PKA can also activate the ERK1/2 signalling pathway and still inhibit cell proliferation (Bornfeldt and Krebs, 1999) . Surprisingly, it has recently been shown that cAMPactivated PKA stimulates cell proliferation by inhibiting ERK1/2, thereby favouring activation of the PI3 K signalling pathway (Ciullo et al., 2000) . Thus, the various data on the effects of PKA/cAMP on cell proliferation are difficult to reconcile and the exact role of the PKA/cAMP pathway in the control of the ERK1/2-mediated cell proliferation remain unclear.
The retinal pigment epithelium (RPE) is a monolayer of highly polarized cells that plays a crucial role in maintaining choroidal and neural retina functions. RPE cells have a limited proliferation capacity, corresponding to the normal increase in retinal area associated with growth and age. After injury to the choroid/retina, RPE cells are exposed to a variety of growth factors and cytokines from the serum, resulting in cell proliferation. RPE cell proliferation is an important step in the pathogenesis of retinal diseases, such as proliferative vitreoretinopathy (PVR), and may be associated with choroidal melanoma which lead to impairment or even loss of vision (Enzmann et al., 1998) . Nothing is known about the signalling and the molecular mechanisms underlying these processes and we still know very little about the intracellular signalling that mediates RPE cell proliferation. ERK1/2 was recently reported to be involved in RPE proliferation stimulated by fibroblast growth factors, but no upstream or downstream activators of the ERK pathway were analysed (Bryckaert et al., 2000) . It would therefore be useful to determine precisely which signalling pathways mediate serum-stimulated RPE cell proliferation, to make it possible to inhibit this process specifically in RPE diseases.
We investigated various aspects of ERK signalling during serum-stimulated RPE cell proliferation using Western blotting and both pharmacological and antisense oligonucleotide strategies to inhibit specific ERK-activated pathways. We also addressed the issue of whether cAMP and/or PKA signal transduction pathways are involved in RPE cell proliferation. Possible cross-talk between these pathways was assessed to investigate the specific control of proliferative diseases.
Results

Ras and raf-1 are key components in signalling for RPE proliferation
Ras is a key component of the signal transduction pathway mediating the proliferation of numerous cells. We therefore investigated the role of Ras signalling in serum-stimulated RPE cells using various inhibitors of Ras synthesis, post-translational modification and activation ( Figure 1 ). Ras farnesylation is essential for the translocation of Ras to the plasma membrane and for its activation. RPE cell treatment with 100 mM of the farnesyl transferase competitor N-acetyl-Sfarnesyl-L-cysteine (AFC) resulted in a 67% reduction 4 cells in untreated cultures on days 3 and 6 respectively. Analysis of cell growth by MTT assay gave similar results and neither the induction of cell death nor apoptosis were observed after cell treatment with Ras inhibitors (data not shown). Thus, Ras played a key role in transmitting signals for serumstimulated RPE cell proliferation.
The MAP kinase pathway is one of the major components of signal transduction mediated by Ras and leading to growth. This pathway consists of a linear cascade of the protein kinases Raf, MEK, and ERK. The ERK proteins are phosphorylated and activated by the dual-specificity kinase MEK, which is phosphorylated and activated by the serine/threonine Figure 1 Effects of Ras inhibition on RPE cell proliferation. RPE cells were seeded in six-well plates at a density of 1.5610 4 cells per well and cultured with basal medium supplemented with 10% FCS for 3 days, as described in Materials and methods. The cells were then incubated with or without the Ras inhibitors for 2 h, the culture medium was removed and the cells stimulated again with serum in the presence or absence of the various Ras inhibitors. The proliferation of RPE cells treated with 100 mM of AFC, 10 mM of manumycin and 2.5 mM FTS and then stimulated with 10% FCS was studied on days 1, 2, 3 and 6 as described in Materials and methods. Cell proliferation analysis by MTT assay gave similar results. No cell death induction was observed in the Ras inhibitor-treated cells over the culture period. Values are the means of three different experiments and differences between means were analysed by the Mann and Whitney test. *P50.05, ***P50.005 kinase Raf (Campbell et al., 1998) . Phosphorylation of Raf-1 at serine 338 is part of Raf-1 activation, whereas, an inhibitory signal via Akt abolishes Raf-1 activity by phosphorylation of serine 259 (Zimmerman and Moelling, 1999) . We analysed the state of activation of Raf-1 in serum-stimulated RPE cells by Western blotting with antibodies that specifically recognize active (ser 338 ) and inhibited (ser 259 ) forms of Raf-1. Although basal levels of Raf-1 activation were detectable in unstimulated RPE cells, we observed a modest increase in the levels of Raf-1 phosphorylation on ser 338 after 10 min of stimulation with serum (maximum increase by a factor of 2.5 to 3) ( Figure  2A ). The levels of Raf-1 phosphorylation decreased thereafter, to basal levels, after 30 min of stimulation. In contrast, no phosphorylation of ser 259 was observed (data not shown). The level of production of Raf-1 was constant over this period of culture (Figure 2A ), suggesting that Raf-1 activation was not due to an increase in Raf-1 production after serum stimulation. These data show that Raf-1 was modestly and transiently activated in RPE cell cultures after serum stimulation. We investigated whether Raf-1 activation was involved in RPE cell proliferation by treating cells with Raf-1 inhibitor 1 (0 -30 mM), a potent and selective inhibitor of Raf-1 and analysing cell proliferation by cell counting ( Figure 2B ). RPE cell treatment with Raf-1 inhibitor 1 reduced cell proliferation in a dose-dependent manner ( Figure 2B ). .8610 4 cells in treated cells after 3 and 7 days of culture respectively), suggesting that activation of Raf-1 might be involved in the proliferation of RPE cells. To confirm the role of Raf-1 in the stimulation of RPE cell proliferation by serum, cultures were treated with As Raf-1 ODNs. We showed by cell counts that the decrease in Raf-1 production by AS Raf-1 ODN-treated cell cultures significantly decreased cell proliferation, by 45 to 53% during the first 2 days of the culture and by 63 to 71% from day 3 to day 7 of the culture period ( Figure 2C ). Mis Raf-1 ODN treatment had no significant effect on cell proliferation ( Figure 2C ). Similar results were obtained with the MTT assay. Thus, Raf-1 was also greatly involved in the signalling pathway of seruminduced RPE cell proliferation.
Inhibition of MEK1/2-ERK1/2 does not lead to complete inhibition of RPE cell proliferation MEK1/2 are the only two commonly accepted downstream substrates of Raf-1, whereas ERK1/2 are the only known substrates for MEK1/2. We then analysed the involvement of MEK1/2 and ERK1/2 in signalling for serum-stimulated RPE cell proliferation. We investigated the state of phosphorylation of MEK1/2 Figure 2 Analysis of Raf-1 activation and effects of Raf-1 inhibition and Raf-1 depletion on RPE cell proliferation. (A) RPE cells were cultured for 3 days, incubated in serum-free medium overnight and then, stimulated with 10% FCS. Cells were lysed at the indicated times and equal amounts of protein were reduced and subjected to SDS -PAGE and Western blotting with an antiactive phosphorylated Raf-1 antibody and an anti-Raf-1 antibody as described in Materials and methods. (B) RPE cells were treated with the indicated amount of Raf-1 inhibitor 1 and cell proliferation was analysed on days 1, 2, 3 and 6 as described in Materials and methods. (C) RPE cells were treated with 1 mM Raf-1 missense (Mis Raf-1) and antisense (AS Raf-1) ODNs in lipofectin (7 mg/ml) and were stimulated with 10% FCS. For detection of Raf-1 by Western blotting, lysate (50 mg of total protein) isolated on days 1, 2, 3, 4 and 7 from cells treated with FCS plus Mis Raf-1 ODN and FCS plus AS Raf-1 ODN was subjected to electrophoresis in 12% polyacrylamide gels containing SDS, transferred to nitrocellulose and Raf-1 protein was detected with a specific polyclonal Raf-1 antibody. . In contrast to the moderate increase in the levels of Raf-1 phosphorylation, the stimulation of RPE cells by serum induced changes in the levels of phosphorylation of MEK1/2 over the 24 h period of culture (Figure 3 ). MEK1/2 phosphorylation was only just detectable before serum stimulation, whereas high levels of MEK1/2 activation were detected within 10 min of the addition of serum ( Figure 3A) . The levels of MEK1/2 phosphorylation remained high for the next 30 min and then returned to basal levels. The production of MEK1/2 was constant over this period of culture ( Figure 3A) . Analysis of the levels of ERK2 phosphorylation showed that ERK2 activation matched that of MEK1/2 ( Figure 3B ). Phosphorylation of ERK2 was barely detectable in the basal state, whereas ERK2 activation peaked within the first 10 min after the addition of serum, remained high for the following 6 h and then decreased ( Figure 3B ). The production of ERK2 was constant over this period of culture. Surprisingly, no activation of ERK1 was detectable over the 24 h culture period. We investigated the role of MEK1/2 activation in RPE proliferation. To determine whether activation of the MEK/ERK signalling pathway by serum was necessary for RPE cell proliferation, we treated serumstimulated cells with the specific pharmacological inhibitor of MEK1/2, UO 126. Cell treatment with 30 mM UO 126 resulted in a strong inhibition of ERK2 activation after 10 and 30 min of culture and thereafter completely abolished ERK1/2, confirming the efficiency of inhibiting MEK1/2 activity for ERK2 activation ( Figure 3C ). RPE cell treatment with up to 30 mM of UO126 resulted in a reduction in serumstimulated RPE cell proliferation by only 21 4 cells in untreated cultures on day 6 of the culture period) over the 6 day period of culture ( Figure 3C ), suggesting that ERK2 activation might be involved in RPE cell proliferation. To confirm the involvement of ERK2 in the proliferation of serumstimulated RPE cells, we downregulated ERK2 production by an antisense oligonucleotide approach. The ERK2 depletion of serum-stimulated RPE cells by treatment with AS ERK1/2 ODNs resulted in a 24% reduction in cell proliferation after 3 days of culture and a 27% reduction (26.7610 4 +3610 4 cells in AS-transfected cell cultures versus 38.96 10 4 +5610 4 cells in control cultures on day 7 of the culture period) after a 7 day period of culture ( Figure  3D ). In contrast, cell treatment with S ERK1/2 ODN did not significantly affect serum-stimulated cell proliferation. These data strongly suggest that ERK2 partially mediated serum signalling for RPE cell proliferation. Figure 3 Analysis of MEK1/2 and ERK2 activation, and effects of MEK1/2 inhibition and ERK2 depletion on ERK2 activation and cell proliferation in FCS-stimulated RPE cells. RPE cells were cultured in DMEM supplemented with 10% FCS for 3 days (A, B, and C), incubated in serum-free medium overnight and then stimulated with 10% FCS. Cells were lysed at the times indicated and equal amounts of protein were reduced and subjected to SDS -PAGE and Western blotting with anti-active phosphorylated MEK1/2 and anti-MEK1 (A) antibodies, and anti-active phosphorylated ERK1/2 (B) and anti-ERK2 (B and C) antibodies as described in Materials and methods. RPE cells were treated with the MEK1/2 inhibitor UO 126 (UO) at the indicated concentrations and cell proliferation was analysed as described in Materials and methods (C). For analysis of the effects of ERK1/2 depletion on serum-induced RPE cell proliferation, RPE cells were treated with 1 mM ERK1/2 sense and antisense ODNs in lipofectin (7 mg/ml) and were stimulated with 10% FCS (D). For the detection of ERK2 by Western blotting, lysate (20 mg of total protein) isolated on days 1, 2, 3 and 7 from cells treated with FCS plus ERK1/2 sense (S ERK1/2) ODN and FCS plus ERK1/2 antisense (AS ERK1/2) ODN was subjected to electrophoresis in 15% polyacrylamide gels containing SDS, transferred to nitrocellulose and ERK1/2 proteins were detected with a specific polyclonal ERK1/2 antibody. Cell proliferation was analysed on days 1, 3 and 7 of RPE cell cultures treated with lipofectin alone (control), lipofectine plus S ERK1/2 ODN (S ERK2) or lipofectine plus antisense ERK1/2 ODN (AS ERK2). Cell proliferation was analysed by cell counting after Trypan blue exclusion. Determination of the effects of ERK1/2 downregulation on cell proliferation by MTT assay gave similar results. No cell death or apoptosis was detected in UO 126-treated cells and AS ERK1/2-treated cells, in comparisons with DMSO-treated cells and S ERK1/2 ODN-treated and lipofectin-treated cells. Similar results were obtained in four (A) or three (B, C and D) independent experiments. Value are mean+s.d. and differences between means were analysed by the Mann and Whitney test. *P50.05
Are the signal pathways regulating the activation of Src involved in ERK1/2-mediated RPE cell proliferation?
Recruitment by activated Ras is necessary, but not always sufficient for full activation of Raf. Therefore, other factors necessary for the activation of the ERK pathway may feed into the pathway at Raf and downstream from Raf (Morrison and Cutler, 1997 Figure 4A ). Stimulation of RPE cell proliferation resulted in a strong activation of Src. High levels of serum-mediated phosphorylation of Src were detected after 10 min of culture ( Figure 4A ). The levels of Src phosphorylation remained high for the next 2 h and then returned to basal levels. The production of Src was not altered by serum stimulation ( Figure 4A ). We then investigated the role of activated Src in RPE cell proliferation by counting cells. We first treated serum-treated RPE cells with the selective and potent inhibitor of Src, SU 6656 ( Figure 4B 4 cells in untreated cultures on day 6 of the culture period) serum-stimulated RPE cell proliferation after 3 and 6 days of culture respectively ( Figure 4B ), suggesting that Src is a positive regulator of cell proliferation. In a second set of experiments we inhibited three members of the Src family, p56 lck , P59 fyn and Hck, with the Src family kinase inhibitor, PP2 ( Figure 4C ). Cell proliferation was not significantly affected by PP2 treatment at concentrations of up to 20 mM over the 6-day period of culture, suggesting that these three Src kinases were not involved in serum-stimulated RPE cell growth.
Are nuclear translocation and nuclear export of ERK1/2 involved in the partial role of ERK1/2 in RPE cell proliferation?
Our data showed that RPE cell proliferation was only partially mediated by the MEK/ERK signalling pathway. It is possible that the activation of ERK signalling is altered, limiting its role in mediating RPE cell proliferation and thereby accounting for the partial effect of UO 126. In response to mitogenic stimuli, ERK1/2, which are present in the cytoplasm of quiescent cells, are translocated to the nucleus in a phosphorylated form (Khokhlatchev et al., 1998) . The nuclear translocation of phosphorylated ERK1/2 is the limiting step in the transcriptional activity of ERK1/2 and is necessary for the induction and activation of nuclear transcription factors and cell proliferation. Thus, the absence of or a decrease in translocation to the nucleus of phosphorylated ERK1/2 in serumstimulated RPE cells would limit cell proliferation. Moreover, it has been recently demonstrated that non phosphorylated MEK1/2 are also translocated to the nucleus and associated with ERK1/2 to convey ERK1/ 2 from the nucleus to the cytoplasm (Adachi et al., 2000) . So, nuclear export of ERK1/2 may function to restore the cytoplasmic pool of ERK1/2 available for activation in the next stimulation, thereby ensuring the Figure 4 Analysis of Src activation and effects of the inhibition of Src activity on cell proliferation in FCS-stimulated RPE cell cultures. (A) RPE cells were cultured in DMEM supplemented with 10% FCS for 3 days, incubated in serum-free medium overnight and then stimulated with 10% FCS. Cells were lysed at the times indicated and equal amounts of protein were reduced and subjected to SDS -PAGE and Western blotting with anti-phosphorylated Src, and anti-Src antibodies (A) as described in Materials and methods. Cultures of FCS-stimulated cells were treated with SU 6656, the Src inhibitor (B), and with the Src kinase family inhibitor, PP2, at the indicated concentrations (C). Cell proliferation was analysed on days 1, 3 and 6 by cell counting after Trypan blue exclusion, as described in Materials and methods. Similar results were obtained with the MTT assay. Values are means+s.d. and differences between means were analysed by the Mann and Whitney test. *P50.05, **P50.01, ***P50.005 sustained continuous activation of the ERK1/2 cascade. Thus, the lack of relocalization of unphosphorylated ERK1/2 and MEK1/2 to the cytoplasm would also limit cell proliferation. The nuclear translocation of phosphorylated ERK1/2 was investigated by immunochemistry, using an antibody that specifically recognizes only activated phosphorylated forms of ERK1/2. The export of ERK2 and MEK from the nucleus to the cytoplasm was investigated using antibodies that recognize total ERK2 and MEK1/2, because only dephosphorylated ERK2 binds MEK1/2 (Adachi et al., 1999) . Immunostaining for phosphorylated ERK2 showed that the active form of ERK1/2 was not present in the cytoplasm of unstimulated RPE cells ( Figure 5A ). After 15 min of serum-stimulated culture, active ERK2 staining was detectable in the cytoplasm of some cells, whereas most of the nuclei were strongly stained ( Figure 5B) . After 2 h of culture, staining for phosphorylated ERK2 was no longer observed in the nuclei of the majority of stimulated cells and no staining for active ERK2 was detected in the cytoplasm ( Figure 5C ). Thus, following FCS stimulation, active ERK2 was not re-exported to the cytoplasm after entry into the nucleus. Treatment with UO 126 for 15 min abolished phosphorylated ERK2 staining in serum-stimulated cells ( Figure 5D ), confirming the efficiency of the MEK1/2 inhibitor. No immunostaining was observed if cells were incubated with antibody against active phosphorylated forms of ERK2, preadsorbed with an excess of the phosphopeptide corresponding to the phosphorylated sequence of active ERK1/2 ( Figure 5E ). Immunochemical analysis of ERK2 showed that ERK2 staining was confined exclusively to the cytoplasm of unstimulated RPE cells ( Figure 5F ). After 15 min of FCS stimulation, ERK2 staining was still detected in the cytoplasm, whereas ERK2 staining was detectable in the nuclei of all stimulated cells ( Figure 5G) . After 2 h of stimulation with FCS, ERK2 staining was no longer present in the nuclei, whereas ERK2 staining was still present in the cytoplasm of the majority of stimulated cells ( Figure  5H ), suggesting that ERK2 was rapidly excluded from the nucleus. In addition, RPE cell treatment with the MEK1/2 inhibitor for 15 min resulted in the loss of ERK2 staining in the nuclei, but not in the cytoplasm of stimulated cells ( Figure 5I ), confirming that ERK2 activation was required for ERK2 nuclear translocation. No immunostaining was observed with nonimmune serum ( Figure 5J ). These data show that phosphorylated ERK2 was translocated to the nuclei of serumstimulated cells and that remained for a short period of time in the nucleus and was then re-exported to the cytoplasm. In contrast to ERK2 staining, strong MEK1/2 staining was detected in the cytoplasm of unstimulated cells ( Figure 5K ). MEK1/2 was still present in the cytoplasm of the majority of the cells after 15 min of stimulation ( Figure 5L ). After 2 h of culture, MEK1/2 staining was still detected within the cytoplasm ( Figure 5M ), suggesting that MEK1/2 localizes to the cytoplasm irrespective of its activation state. Moreover, MEK1/2 immunostaining was not altered in serum-stimulated cells after treatment with UO 126 for 15 min ( Figure 5N ), suggesting that the intracellular localization of MEK1/2 did not depend on MEK1/2 activation. No immunostaining was detected if the primary antibody was omitted ( Figure 5O ). Overall, these data suggest that the partial effect of ERK2 on RPE cell proliferation was not due to a partial blockade of nuclear translocation of phosphorylated ERK2 and of nuclear export of activation-competent ERK2 in stimulated cells.
Do PKA and cAMP regulate RPE cell proliferation?
Complex cross-talk between PKA and the ERK1/2 pathway resulting in growth inhibition has been described (Bornfeldt and Krebs, 1999) . This might account for the transient ERK1/2 activity and the partial effect of UO 126 on RPE cell proliferation. The exact point at which the MAP kinase cascade is inhibited by PKA is still a matter of debate. We treated RPE cells with the potent selective PKA inhibitor H89 to investigate possible cross-talk between PKA and ERK. Cell treatment with H89 (0 -10 mM) had no significant effect during the first 3 days of culture ( Figure 6A ). In contrast, 10 mM H89 reduced cell proliferation by 35% over the last 3 days of the 6-day culture period, showing that the PKA pathway is not a Figure 5 Analysis of ERK1/2 nuclear translocation. Immunostaining for the active phosphorylated forms of ERK1/2 (A -E), for total ERK2 (F -J) and for total MEK1/2 (K -O) was performed after overnight incubation in a serum-free culture medium (A, F and K), and 15 min (B, G and H) and 2 h in the absence (C, H and M) and in the presence (D, I and N) of UO 126, after the FCS stimulation of RPE cells. The specificity of anti-phosphorylated ERK1/2 immunoreactivity was checked by incubating an excess of the phospho-peptide corresponding to the phosphorylated sequence of active ERK1/2 with antibody against active phosphorylated forms of ERK2 (E). No immunostaining was detected with nonimmune serum (J) if the primary antibody was omitted (O). Similar results were obtained in three independent experiments Involvement of ERK and cAMP signalling in RPE cell proliferation C Hecquet et al negative effector, but a late positive regulator of RPE cell proliferation. Interestingly, it has recently been reported that Rap1, a member of the Ras family, can be activated by cAMP, and antagonizes Ras-dependent signalling in a PKAindependent manner (Hu et al., 1999) . Thus, we treated serum-stimulated RPE cells with two agents that increase cAMP concentration, IBMX and cholera toxin, and analysed cell proliferation by cell counting after Trypan blue exclusion. After 6 days of treatment, IBMX (100 mM), an inhibitor of cAMP phosphodiesterases, reduced cell proliferation by 31%, whereas cholera toxin (10 ng/ml), a potent activator of adenylate cyclase, reduced cell proliferation by 53% ( Figure 6B ). Cell treatment with a combination of IBMX plus cholera toxin reduced cell proliferation by 78% after 6 days of culture, showing that these agents have an additive effect on RPE cell proliferation ( Figure 6B ). We therefore thought that cAMP might activate Rap1 to antagonize Ras-dependent RPE cell proliferation. Serum-stimulated cells were treated with GGTI-298 (25 mM), a potent and selective inhibitor of the Rap1 processing and with a combination of IBMX plus cholera toxin ( Figure 6C ). Inhibition of Rap1 decreased by 68 -87% the inhibitory effects of a combination of IBMX plus cholera toxin on cell proliferation over the 6 day period of culture ( Figure 6C ), suggesting that Rap1 partially mediated the inhibitory effects of the agents that increased cAMP concentration.
Analysis of the signalling target of the Rap1/cAMP growth inhibitory pathway
The inhibitory effects on RPE cell proliferation of Rap1 and agents that increase cAMP-concentration and the lack of effect on cell proliferation of the PKA inhibitor suggest that cAMP and Rap1 may inhibit RPE cell proliferation through inhibition of ERK1/2 activation. To confirm this hypothesis, serum-stimulated RPE cells were treated with the specific PKA inhibitor, H89, or with GGTI-298 (25 mM) with or without a combination of IBMX plus cholera toxin, and the state of ERK1/2 activation was investigated by Western blotting. RPE cell treatment with H89 did not alter the kinetics of ERK1/2 activation nor levels of ERK2 production over the 24 h period of culture ( Figure 7A ), confirming that PKA has no inhibitory effect on the cell signalling-mediated RPE cell proliferation. In striking contrast, the treatment of serumstimulated cells with a combination of IBMX plus cholera toxin greatly reduced levels of ERK1/2 activation after 10 min of culture and completely abolished ERK1/2 activation after 2 h of culture and over the 24 h period of culture ( Figure 7B ). cAMP did not alter the levels of ERK2 production ( Figure 7B ). These results suggest that agents increasing the concentration of cAMP may exert their inhibitory effects on cell proliferation through the inhibition of ERK1/2 activation. Inhibition of Rap1 in cell cultures treated with a combination of IBMX plus cholera toxin abolished the inhibitory effects on ERK1/2 activation of agents increasing cAMP concentration ( Figure 7C ), demonstrating that the inhibition of cell proliferation of these agents may be mediated by Rap1, through the inhibition of ERK1/2 activation. However, the pharmacological inhibition of MEK1/2 activation, which resulted in the inhibition of ERK1/2, induced only a 30% decrease in cell proliferation, whereas agents increasing cAMP production decreased cell proliferation by 70%. This suggests that cAMP may exert its inhibitory effects at another point in the MAPK cascade, upstream from ERK1/2. As Raf-1 inhibition resulted in stronger inhibitory effects on cell prolifera- Figure 6 Effects of the inhibition of PKA and Rap1, and of agents increasing cAMP levels on serum-induced RPE cell proliferation. Effects of the inactivation of Rap1 on the cAMPmediated inhibition of serum-induced RPE cell proliferation. Cultures of FCS-stimulated cells were treated with the indicated concentration of the PKA inhibitor H89 (A), with the two cAMP concentration-increasing agents, IBMX (100 mM) and cholera toxin (10 ng/ml), alone (B) and in combination (B and C), and with the indicated concentration of the Rap1 inhibitor, GGTI-298 (C). Cell proliferation was analysed as described in Materials and methods. To test the effects of the inactivation of Rap1 on the role of cAMP in serum-stimulated cells, RPE cell cultures were first treated with GGTI-298 (25 mM) for 2 h, then with a combination of IBMX plus cholera toxin and cell proliferation was analysed as described in Materials and methods (C). Similar results were obtained in three independent experiments. Values are means+s.d. and differences between means were analysed by the Mann and Whitney test. NS: non significant, *P50.05, **P50.01, ***P40.005 tion (up to 63%) than did ERK1/2 inhibition, we thought that raf-1 might be the target of cAMP inhibitory effect, within the MAPK cascade. Thus, we analysed the effects of cAMP and of Rap1 inhibition on the direct downstream kinase activated by Raf-1, MEK1/2. Analysis of MEK1/2 phosphorylation in serum-stimulated RPE cells treated with and without agents increasing cAMP concentration showed that cAMP also reduced MEK1/2 activation ( Figure 8A ), whereas the inhibition of Rap1 in cells treated with agents that increased cAMP reversed the inhibitory effects of these agents on MEK1/2 activation ( Figure  8B ). These results strongly suggest that Rap1/cAMP inhibited RPE cell proliferation through inhibition of the Ras/ERK1/2 pathway at the level of MEK1/2 activation or upstream from this point.
Discussion
The ERK1/2 signalling pathway controls various RPE cell activities
The aim of this study was to determine whether the MAP kinase/ERK signalling pathway is involved in the proliferation of RPE cells stimulated by serum. However, both positive and negative regulating effects on cell proliferation have been demonstrated for the MAP kinase pathway. It has recently been shown that ERK1/2 transmits anti-apoptotic signals in serumdepleted RPE cell cultures (Guillonneau et al., 1998; Bryckaert et al., 2000) . In this study, we demonstrate that ERK2 also controls cell proliferation in serumstimulated RPE cell cultures, suggesting that ERK2 may control different cell fate, proliferation and survival, in the same cell type.
The small GTPase Ras has been shown to play a crucial role in transmitting signals leading to ERK1/2 activation and cell proliferation. Indeed, using three different pharmacological agents that block Ras activation at different levels of Ras metabolism, we showed that Ras plays a major role in serum-induced RPE cell proliferation. Although basal levels of Raf-1 Figure 7 Effects of the inhibition of PKA, of the inactivation of Rap1 and of agents increasing cAMP levels on ERK1/2 activation and production in serum-induced RPE cell cultures. Cultures of FCS-stimulated cells were treated with the indicated concentration of the PKA inhibitor H89 (A) or with the two cAMP concentration-increasing agents, IBMX (100 mM) and cholera toxin (10 ng/ml) in combination (B). Cultures of FCS-stimulated cells were also treated with the Rap1 inhibitor for 2 h and then treated with the two cAMP concentration-increasing agents, IBMX (100 mM) and cholera toxin (10 ng/ml) in combination (C). Lysate (50 mg of total protein) was subjected to electrophoresis in 15% polyacrylamide gels containing SDS and transferred to nitrocellulose. Phosphorylated ERK1/2 and ERK2 were detected with specific anti-phosphorylated ERK1/2 and anti-ERK2 antibodies respectively. Similar results were obtained in two (A) and three (B and C) independent experiments Figure 8 Effects of the inhibition of PKA, of the inactivation of Rap1 and of agents increasing cAMP levels on MEK1/2 activation and production in serum-induced RPE cell cultures. Cultures of FCS-stimulated cells were treated with or without the indicated concentration of the two cAMP concentration-increasing agents, IBMX (100 mM) and cholera toxin (10 ng/ml) in combination (A). Cultures of FCS-stimulated cells were also pre-treated with the Rap1 inhibitor (GGTI) for 2 h and then treated with the two cAMP concentration-increasing agents, IBMX (100 mM) and cholera toxin (10 ng/ml) in combination (B). Lysate (50 mg of total protein) was subjected to electrophoresis in 15% polyacrylamide gels containing SDS and transferred to nitrocellulose. Phosphorylated MEK1/2 and MEK1/2 were detected with specific anti-phosphorylated MEK1/2 and anti-MEK1/2 antibodies respectively. Similar results were obtained in three (A and B) independent experiments Involvement of ERK and cAMP signalling in RPE cell proliferation C Hecquet et al activation were high, even when RPE cells were not stimulated by serum, Raf-1 was activated and was clearly an important component of the signalling pathway of RPE cell proliferation because Raf-1 inhibition by pharmacological and antisense ODNs strategies reduces cell proliferation. Both MEK1/2 and ERK2 were strongly, but transiently activated following serum stimulation and the kinetics of phosphorylation for MEK1/2 and ERK were very similar. Thus, serum-induced signalling for RPE cell proliferation probably follows the linear signalling cascade of Ras/Raf/MEK/ERK. Transient activation of ERK2 is observed during cell proliferation in serumstimulated RPE cell cultures, whereas sustained ERK2 activation is correlated with anti-apoptotic activity of FGF2 in serum-depleted RPE cell cultures (Guillonneau et al., 1998) . This suggests that the differences in ERK2 kinetics may determine cell fate, proliferation or survival. The regulation of biological activities by the level and duration of ERK2 activation has been observed in PC12 cell lines and may also be involved in control and regulation of RPE cell activities. The duration of the kinetics of ERK2 activation and its translocation to the nucleus may determine the activity of ERK2 and activation of the downstream targets of ERK2. Our immunochemical data confirm that ERK2 is rapidly translocated in large amounts to RPE cell nuclei after serum stimulation suggesting that the partial effect of ERK2 on RPE cell proliferation is not due to a partial blockade of nuclear translocation of phosphorylated ERK2 in stimulated cells.
Cross-talk at MEK/ERK for serum-induced RPE cell proliferation
Pharmacological inhibition of MEK1/2 activity and ERK1/2 activation, and antisense ODN-mediated inhibition of ERK1/2 production induced a decrease in RPE cell proliferation smaller than that observed after Ras blockade and, to a lesser extent, after Raf-1 inhibition and downregulation. A major signalling pathway that crosstalks with ERK for cell proliferation is the PKA pathway. In some cell types, and under certain circumstances, activation of PKA results in activation of the ERK1/2 pathway, whereas in other cell types and under other culture conditions, PKA blocks ERK1/2 signalling for cell proliferation (Bornfeldt and Krebs, 1999). Although PKA-ERK1/2 crosstalk has been widely studied, the precise mechanisms involved in this process remain to be precisely defined. ERK signalling can inhibit smooth muscle cell proliferation through the stimulation of the cytosolic form of phospholipase A2 (cPLA2) (Bornfeldt and Krebs, 1999) . Activation of cPLA2 results in generation of arachidonic acid, followed by synthesis and secretion of prostglandins that lead to production of cAMP and subsequent autocrine activation of PKA. PKA has been shown to inhibit cell cycle by antagonizing mitogenic signalling pathway. In our study, the inhibition of PKA had no inhibitory effect on serum-induced RPE cell proliferation. These data rule out the possibility of inhibitory cross-talk between PKA and ERK signalling in RPE cell proliferation. Although inhibition of PKA did not alter RPE cell proliferation, an increase of cAMP level induced a rapid and strong inhibition of serum-induced RPE cell proliferation. cAMP can interact directly with some ion channels, but most cAMP-mediated effects have been considered to involve cAMP binding by PKA. cAMP can inhibit or stimulate the Ras/ERK pathway. Rap1, a member of the Ras family, discovered as a negative regulator of Ras in some cell lines, has been reported to be activated by PKA and by cAMP in a PKAindependent manner (Hu et al., 1999) . However, the physiological role of Rap1 remains to be elucidated. We therefore investigated the role of Rap1 in RPE cell proliferation and showed that Rap1 controls cAMPmediated RPE cell proliferation, because Rap1 inhibition reversed the inhibitory effects of cAMP. The exact point of inhibition of the Ras/MEK/ERK cascade by cAMP/Rap1 is still a matter of debate and it is possible that cAMP/Rap1 may have different specific targets within the Ras/MAPK signalling pathway. We demonstrated that the direct target of the Rap1/cAMP inhibitory pathway is the Ras/MAPK signalling pathway, because both MEK1/2 and ERK1/2 activation were blocked by agents that increased cAMP levels and the inhibition of both MEK1/2 and ERK1/2 activation and cell proliferation was reversed by Rap1 inhibitor. Our study confirms recent data showing that Rap1 is required not only for cAMP-mediated inhibition of ERK1/2 activation, but also for the inhibition of cell proliferation in NIH3T3 cells (Schmitt and Stork, 2001) . Our data also suggest that activation of the upstream activator of MEK1/2, Raf-1, is the main target of cAMP/rap1 for cell proliferation, confirming that the initial translocation step by which Ras activates Raf-1 may be a target of the inhibitory effects of cAMP/Rap1 (Cook and McCormick, 1993) . It is interesting to note that the inhibition of Rap1 does not totally reverse the inhibition of RPE cell proliferation mediated by agents that increase cAMP levels, suggesting the existence of Rap1-independent cAMP inhibitory pathway.
The inhibition of ERK1/2 and MEK1/2 resulted in approximately 30 and 40% inhibition of cell proliferation, respectively, whereas cAMP/Rap1 inhibited cell proliferation by approximately 70%. This suggests that cAMP/Rap1 might exert their inhibitory effects on another signalling pathway involved in cell proliferation. Cyclic AMP has also been shown to regulate the phosphatidylinositol 3-kinase (PI 3-K), Akt and/or P70 S6 kinase in many cells, although the mechanisms by which this occurs are largely uncharacterized (Kim et al., 2001) . In addition, it has been shown that the ERK and PI 3-K signalling pathways function in parallel and that there is cross-talk between these two pathways (Zubilewicz et al., 2001a) . It has also been shown that PI 3-K is required for ERK activation for the control of cell proliferation (Zubilewicz et al., 2001b) . Thus, it is possible that the PI 3-K signalling pathway is activated and required for RPE cell proliferation. It would therefore be interesting to study possible crosstalk between ERK and PI 3-K for the activation of RPE cell proliferation and between PI 3-K and cAMP/ Rap1 for the inhibition of RPE cell proliferation.
Another mechanism by which cAMP may inhibit the Ras/MAPK signalling pathway involves the inhibition of kinases that can activate Raf-1, such as certain isoforms of protein kinases C (PKC) or Src (Magnuson et al., 1994) . We have demonstrated that Src also play a key role in the activation of RPE cell proliferation. It would therefore be of interest to analyse the effects of cAMP/Rap1 on Src activation, the potential role of PKC in mediating signalling for RPE cell proliferation and possible cross-talk between cAMP/Rap1 and PKC signalling during RPE cell proliferation. Moreover, agents that increase cAMP levels have also been shown to act directly on the cell cycle machinery. They downregulate the production of cyclins, such as cyclin D1, and of cyclin-dependent kinases, such as cdk2, and upregulate the cdk inhibitor p27Kip, resulting in inhibition of the transition from the G1 phase of the cell cycle to the S phase (Bornfeldt and Krebs, 1999) . It would therefore be interesting to study the role of the Ras/MAPK signalling pathway and the effects of cAMP/Rap1 on the production levels of these components in RPE cells.
In conclusion, our data show for the first time that the Ras/Raf-1/MEK/ERK pathway is a signalling pathway involved in RPE cell proliferation that is tightly regulated by a PKA-independent cAMP signalling pathway, which is mainly controlled by Rap1. Further studies are required to investigate the role of such cross-talk in RPE cell proliferation in vivo. Identification of the complete kinase signalling network, its substrates, and potential regulatory loops may help us to develop selective methods and strategies for the treatment of proliferative diseases involving RPE cells.
Materials and methods
RPE culture and treatment of cells
Primary bovine RPE cell cultures were grown in Dulbecco's modified essential medium (DMEM, GIBCO -BRL, NY, USA) supplemented with 10% foetal calf serum (FCS, GIBCO -BRL, NY, USA), 1.25 mg/ml fungizone, 50 mg/ml gentamycin and 2 mM L-glutamine as previously described (Guillonneau et al., 1998) . Primary human RPE cell cultures were seeded on 0.1% gelatin-coated dishes and grown in F99RPE growth medium as previously described (Valtink et al., 1999) . Subcultures were grown in F99 basal medium (medium 199/Ham's F12, GIBCO -BRL, NY, USA), containing 10% FCS and supplemented with 1 mM sodium pyruvate, 1 mg/ml insulin, 50 mg/ml gentamycin and 25 mg/ml amphotericin B.
In some experiments, specific inhibitors of Ras (manumycin, AFC and FTS), Raf-1 (Raf-1 inhibitor 1), MEK1/2 (UO126), PKA (H89) and Rap1 (GGT1-298) (Calbiochem, Meudon, France) and agents increasing cAMP concentration, IBMX and cholera toxin, were used to analyse the role of various intermediates of the ERK1/2 and cAMP/PKA signalling pathways in RPE cell proliferation. RPE cells were seeded at a density of 5610 4 cells per well in six-well plates and were cultured for 3 to 4 days. Cells were then incubated with or without specific inhibitors for 2 h before the induction of cell proliferation. We induced cell by adding 10% FCS in the presence or absence of the specific inhibitor (day zero of the cell proliferation kinetics study). Three days later, culture media was removed and cell proliferation was stimulated again by adding 10% FCS in the presence or absence of the specific inhibitors and incubating for a further 3 to 4 days. Cell proliferation was measured before the induction of cell proliferation with serum and daily after the induction of cell proliferation over a 7-day period of culture. Stock solutions of each inhibitor were made in DMSO diluted in serum-free culture media so that the final concentration of DMSO in test solutions would not exceed 0.1% (a concentration which has no effect on RPE cell proliferation). The efficiency of each inhibitor was checked by Western blot analysis of protein lysates from serumstimulated RPE cell cultures. The inhibitors were used at concentrations within the range described as non-toxic by the manufacturer. However, we checked that there was no toxicity by checking (1) that the inhibitor-treated cells proliferated after washing and replacement of the inhibitorcontaining medium with fresh inhibitor-free medium; (2) that the inhibitor-treated cells synthesized actin at levels similar to those of untreated cells and (3) the lack of toxic and cell proliferation inhibition effects of high concentrations of negative control, corresponding to structural analogues of the inhibitors (when provided by the manufacturer). In no case was cell toxicity observed in the inhibitor-treated cells.
The proliferation of RPE cells was assessed daily by two methods: (1) counting the cells remaining in the culture dish after staining with Trypan blue; and (2) using MTT (3 (4,5-dimethylthiazol-yl) 2,5 diphenyltetrazolium bromide (Guillonneau et al., 1998) . In no case did the number of Trypan blue-positive cells exceed 8% of the total cell population. Cells were examined by phase-contrast microscopy before cell treatment and before MTT, to assess the degree of cell death visually. Cell death was checked by staining the cell nuclei with Hoechst 33258 (0.5 mg/ml). Apoptotic bodies and chromatin condensation were detected with a Leitz Aristoplan microscope equipped with epifluorescence illumination, after staining cell nuclei with DAPI. The percentage of cell proliferation was calculated by comparison with the control DMSO-treated cells.
Western blot analysis
RPE cells were washed twice in PBS, lysed in ice-cold lysis buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 50 mM NaF, 5 mM EDTA, 40 mM b-glycerophosphate, 0.2 mM sodium orthovanadate, 1 mg/ml leupeptin, 1 mM pepstatin) and centrifuged at 48C for 10 min at 10 000 g. Monoclonal antibody directed against b-actin was used as an internal standard for checking protein loading. Cell lysates were mixed with 36 Laemmli buffer and heated for 5 min at 958C. They were then resolved by SDS -PAGE (12 -15% polyacrylamide gel), transferred onto nitrocellulose filters by electroblotting and probed with polyclonal antibodies directed against Raf-1, MEK1, ERK1 and 2 (dilution 1 : 100, Santa Cruz, CA, USA) to determine the amount of these kinases over the proliferation period. A polyclonal antibody directed against phospho-ERK1/2 (thr 192 and tyr 194 ) (dilution 1 : 5000, Promega, WI, USA) and polyclonal antibodies directed against phospho-Raf-1 (ser 338 , dilution 1 : 1000, Chemicon, USA) and phospho-Raf-1 (Tyr  340 and Involvement of ERK and cAMP signalling in RPE cell proliferation C Hecquet et al tyr 341 , dilution 1/1000, Biosource, Belgium) and polyclonal antibodies directed against phospho-MEK1/2 (ser 217 and ser 221 ) (dilution 1 : 2000, New England Biolabs/Cell Signalling Technology, MA, USA) were used to analyse the activation of intracellular signalling during RPE proliferation. The primary antibodies were detected with a horseradish peroxidase-conjugated goat anti-rabbit secondary antibody. ECL substrate was used to reveal bands, according to the manufacturer's instructions, and the membrane was placed against Hyperfilm TM ECL (Amersham, Orsay, France). The bands on the fluorograph were quantified with an LKB Ultrascan XL laser densitometer (Pharmacia, Saclay, France).
Immunohistochemistry
The nuclear translocation of phosphorylated ERK1/2 was confirmed by immunostaining. RPE cells plated on glass coverslips were fixed with 4% paraformaldehyde (PAF) for 15 min at room temperature at various times after culture stimulation with 10% FCS. Cells were thoroughly washed with PBS, treated with ice-cold methanol for 20 min, washed twice with PBS and incubated with anti-phosphorylated ERK1/2, anti-ERK2 and anti-MEK1/2 antibodies (1 : 1000) for 1 h. Control experiments were carried out with antibody against phosphorylated ERK2 preadsorbed with an excess of the phospho-peptide corresponding to the phosphorylated sequence of active ERK2 (Sigma, Saint Quentin-Fallavier, France). Antigen-antibody complexes were detected with rhodamine isothiocyanate-conjugated anti-rabbit antibody (1 : 100) (Biosys, Compiegne, France). Cells were washed with PBS and mounted in glycerol/PBS (1/1).
Oligonucleotides and oligonucleotide treatment of the cells
Phosphorothioate sense and antisense oligonucleotides (ODNs) directed against ERK2 were designed based on the published sequence of the mouse ERK2 gene (Her et al., 1991) . The sequence of the sense ODN was identical to those of ERK1 and ERK2 conserved in human, mouse and rat. The antisense ODN was 5'-GCC-GCC-GCC-GCC-GCC-AT-3' (referred to as AS ERK1/2) and the corresponding sense ODN was 5'-ATG-GCG-GCG-GCG-GCG-GC-3' (referred to as S ERK1/2). Sense and antisense phosphorothioate ODNs directed against Raf-1 were designed based on the published sequence of the human Raf-1 gene. The sense ODN sequence was identical to those of Raf-1 conserved in human, mouse and rat. The antisense ODN targeted the 3'-untranslated region of raf-1 mRNA (Monia et al., 1996) . The AS Raf-1 ODN was 5'-TCC-CGC-CTG-TGA-CAT-GCA-TT-3' (referred to as AS Raf-1) and the mismatched control analogue of AS Raf-1 ODN containing seven base changes with respect to the AS Raf-1 sequence, was 5'-TCC-CGC-GCA-CTT-GAT-GCT-TT-3' (referred to as Mis Raf-1). The antisense ODN was the most potent antisense inhibitor identified, reducing tumour growth and decreasing metastatic potential in a model of human melanoma. We used lipofectin (Gibco -BRL, Cergy Pontoise, France) as a cationic lipid for ODN delivery because this method results in high levels of uptake and stability of ODNs in the intracellular compartment without affecting the final nuclear location of ODNs after endocytosis and release from the endocytic compartment. All ODNs were synthesized commercially (Life Technology, France) and purified by HPLC. Lipofectin-ODN complexes were produced according to the manufacturer's instructions. Preliminary experiments were performed with 2.5, 7 and 10 mg/ml of lipofectin and various concentrations of ODNs (between 0.1 and 4 mM). All results presented here were obtained with 1 mM ODNs for ERK1/2 and Raf-1. Cells were incubated for 3 days in the presence of 10% heat-treated calf serum. RPE cells were then treated with ODNs/lipofectin for 4 h, washed twice with serum-free DMEM medium and fresh growth culture medium was added with the appropriate concentration of ODN. The cells were cultured for 7 days. For 3 days, beginning on day 4 of incubation, cells were treated with the appropriate concentration of ODN without lipofectin. The percentage of cells proliferating was calculated by comparison with control lipofectin-treated cells.
Statistics
Each figure shows the results of experiments repeated at least three times. Data are expressed as the mean+standard deviation of the mean. Two-tailed Student's t-tests (normal distributions with equal variance) and the Mann and Whitney tests (non-parametric) were used for statistical analysis.
